key: cord-0860493-wvjjhqzo authors: Bian, Sumin; Zhu, Bowen; Rong, Guoguang; Sawan, Mohamad title: Towards Wearable and Implantable Continuous Drug Monitoring: A Review date: 2020-08-15 journal: J Pharm Anal DOI: 10.1016/j.jpha.2020.08.001 sha: 4c46f436f8d49ff6014583f268500fa9f13c8572 doc_id: 860493 cord_uid: wvjjhqzo Continuous drug monitoring is a promising alternative to current therapeutic drug monitoring strategies and has strong potential to reshape our understanding of pharmacokinetic variability and to improve individualised therapy. This review highlights recent advances in biosensing technologies that support continuous drug monitoring in real time. We focus primarily on aptamer-based biosensors, wearable and implantable devices. Emphasis is given to the approaches employed in constructing biosensors. We pay attention to sensors’ biocompatibility, calibration performance, long-term characteristics stability and measurement quality. In the end, we discuss about the current challenges and issues to address in continuous drug monitoring to make it a promising, future tool for individualised therapy. The ongoing efforts are expected to result in fully integrated implantable drug biosensing technology. Thus, we may anticipate an era of advanced healthcare in which wearable and implantable biochips automatically adjust drug dosing in response to patient health conditions enabling the management of diseases and enhancing individualised therapy. To achieve CDM, biosensing technologies should meet multiple requirements. First, the transducer, including the target identification, requires to handle the drugs in matrices such as sweat and fresh bloodstream. Also, it should be delivered continuously to the sensor surface for detection. The later may require either a sample collection interface or a microfluidic channel. The transducer includes also the biorecognition phase which needs elements with high-specificity and capability to capture the target in real-time. Next, a data convertor and signal processing core are required to handle the interaction of drug with biorecognition elements which provoke changes in electrical properties. The later changes should be sensitively sensed out in real time. Besides, the sensor should be utilized in a simple label-free, reagent-free, and wash-free process. The final step is signal processing of resulting electrical signals, which must be done in real-time too to enable feedback for immediate decision making. The electrochemical biosensor is a promising tool for achieving CDM. Analytically, electrochemical biosensors allow real-time detection, have a wide linear range of detection, low limits of detection, reproducibility, and optimal stability [23, 24] . Technologically, electrochemical biosensors have extensive applicability, are compatible with advanced microfabrication technologies and state-of-the-art nanotechnologies, at low cost and with minimal power requirements. These made electrochemical biosensors attracting the largest market share in the global biosensors market in 2018, with broad application in continuously monitoring of targets: from plant signalling pathways and metabolism to physiological parameters in biological systems, and in vivo imaging and sensing in diagnostic medicine [25] [26] [27] [28] . Continuous monitoring of glucose, lactate, biomarkers, and neurotransmitters are the most investigated topics in diagnostic medicine [29, 30] . CDM is a relatively new research topic. Limited, though exciting, biosensing technologies have been established in the past to support CDM using a range of emerging nanomaterials, a variety of aptamers, and integration with novel micro/nano systems. In this review, we focus on micro-nano biosensors developed for CDM and operated via electronic and electrochemical signals. Based on the function of the biosensor interface with living body, the micro/nanoscale CDM techniques can be divided into three main categories: in vitro, ex vivo, and in vivo based solutions. In vitro biosensing technologies involve performing measurements in pure buffers or pre-collected blood. Ex vivo biosensing involves validation performed in an artificial environment outside the body. In vivo J o u r n a l P r e -p r o o f validation involves emplaced or implanted devices inside the body. In the subsequent sections of this paper, we describe achievements and undergoing research in biosensing technologies for CDM. Emphasis is given to design approaches to biosensors and the corresponding performance. In Section 2, we focus on in vitro techniques. Ex vivo methods are the subject of Section 3, and Section 4 covers in vivo biosensing technologies. The conclusions of this review are summarised in Section 5 with future perspectives in Section 6. Abbreviations: Artificial intelligence (AI), Internet of Things (IoT). The current practice is complicated and time consuming, involving the drawing of venous blood in a hospital or fingerpick blood collection at home, blood delivery to testing centres, and sample measurement (washing, separation, and sequential addition of reagents). The outcome is a single result or a few parameter values per patient, and the long process hinders the clinician from delivering timely therapy adjustment to the patient. Moreover, the limited drug dosing adjustments fail to guarantee that drug concentrations are always within the proposed therapeutic window, which either causes toxicity or renders the treatment ineffective. In ideal clinical J o u r n a l P r e -p r o o f practice, drug dosing can be adjusted immediately, continuously, or even automatically in response to drug concentrations measured in real time. This would contribute to maximal drug efficacy and minimal adverse effects through the maintenance of constant therapeutic drug concentrations. Such advanced healthcare can be achieved via wearable and implantable biosensors, especially with the aid of the recent advances in artificial intelligence. Electrochemical sensors are the commonly-used devices for in vitro continuous measurements in the sample matrixes include buffer, serum, plasma, and whole blood. Electrochemical biosensors analyse the content of a biological sample through the direct conversion of a biological event into an electronical signal via an electrochemical transductor [31, 32 ]. An electrochemical system comprises a three-electrode sensing cell in direct contact with the target solution, and a potentiostat to drive the measurements and read out the signal [33] . To enhance the biosensing performance, electrode surfaces are either biofunctionalised with various nanomaterials to increase the active sensing areas, or immobilised antibodies or aptamers for specific target capture. Research efforts are subsequently divided into two categories based on the surface modification strategies. Surface modification via functional nanomaterials, such as carbon nanotubes, graphite, or graphene, yield high sensitivity and selectivity, rapid response, and excellent durability in biological media [34] . Baj-Rossi et al. [35] developed an electrochemical biosensor via cyclic voltammetry for continuous monitoring of naproxen, a standard anti-inflammatory compound. The biosensor was developed based on multi-walled carbon nanotubes (MWCNTs) and microsomal cytochrome P4501A2 on a graphite screen-printed electrode, constructed by printing conductive inks on insulating plastic or ceramic substrates. The strategy brought the limit of detection (LOD) down to 16 µM, and enabled real-time monitoring of naproxen for 16 h with high specificity, and greatly simplified sensor preparation. Subsequently, Stradolini et al. [36] presented a pencil graphite electrode (PGE) based electrochemical sensor for long-term cyclic voltammetric monitoring of propofol, a benchmark anaesthetic. Continuous tracking of anaesthetic plasma concentrations is of critical importance to achieving and maintaining a constant level of sedation during surgery. In this study, a clay to graphite ratio of 0.4 was tested and verified to be the most suitable surface modification strategy: the clay content provides a protective shield against fouling while the graphite content supports J o u r n a l P r e -p r o o f electrochemical activity. The sensor monitored propofol for up to 4 h without any intermediate cleaning. Following this study, the group developed a drug monitoring system with an internet of things (IoT) link for continuous and simultaneous online detection of propofol and paracetamol, the two main anaesthetics often administered in combination [37] . The system comprises a microcontroller (Raspberry Pi) used to control and read out the signal from a PGE-based electrochemical sensor. The device includes an IoT network including a cloud-based system that enables physicians to control and share all the patient's data via an Android app and a smart watch ( Fig. 2) . A full capacity test run of the system performed real-time measurement of propofol (60 μM) and paracetamol (300 μM) in undiluted human serum for over 24 min. Real-time monitoring of the two drugs in undiluted human serum for over 24 min [37] . In addition, Sweilam et al. [38] developed a miniaturised, flexible fibre-based sensor for constant detection of lithium, the main antipsychotic drug for treating mood disorders. Functionalised with single-walled carbon nanotubes (SWCNT) and an ion-selective membrane cocktail, the lithium sensor detected lithium in aqueous LiCl solutions without the preconditioning steps required for traditional ion-selective electrodes. Furthermore, the sensors were stable for six months at 4 ℃. The sensor not only continuously monitored lithium over a wide range for up to 26 min in solution, but also produced a linear detection curve for human plasma. This study represents an initial step towards J o u r n a l P r e -p r o o f the design of a wearable sensor for lithium drug monitoring. Aptamers (chemical antibodies) are single-stranded DNA or RNA molecules that can bind to a wide range of targets with high specificity and affinity. They are generated in the systematic evolution of ligands via an exponential enrichment (SELEX) process, which was first reported thirty years ago by Ellington and Szostak [39] and Tuerk and Gold [40] . Compared to antibodies, aptamers are smaller in size, cheaper to produce, and are more easily modified and generated against a wide array of target molecules. Aptamers are highly promising for use in CDM due to their capacity for regeneration (i.e., to be denatured and refolded) multiple times without loss of activity, as well as a long shelf life and good stability [41, 42] . Electrochemical aptamer-based (E-AB) sensors can achieve high selectivity towards a given target because the induced reversible conformational change in aptamer probes occurs only during recognition of the specific target. Furthermore, it is signalled electrochemically, and electroactive impurities within the potential range of the adapted redox tags are rare [43] . In principle, reversible conformational change of the aptamer enhances the rate of electron (e − ) transfer between the redox reporter and the electrode, read out as an electric current. The use of aptamer for real-time, continuous monitoring of drug concentrations was first demonstrated in vitro by Swensen et al. [44] for drug cocaine in human serum, and subsequently, by Li et al. [45, 46] against multiple drugs in undiluted whole blood over multiple hours with good accuracy and precision. Similarly, in two recent studies, an aptamer probe is used in a label-free field-effect transistor-based biosensor and memristive biosensor to monitor tenofovir, an antiretroviral drug for HIV treatment to keep the concentration within its therapeutic range [47, 48] . Both studies have so far achieved real-time detection of tenofovir (<2 min) in human serum with an approximately 1 nM detection limit and good reproducibility after regeneration, which is promising for application in continuous monitoring. Following proven in vitro performance, more research effort is required to investigate potential use of the sensor in ex vivo conditions. An ex vivo environment implies either body biofluids (e.g., sweat and interstitial fluids) collected from the human body or their artificial environment, or fresh blood J o u r n a l P r e -p r o o f drawn directly from the body via catheters. The first microchip to detect drug concentrations directly in the bloodstream of living subjects is an ex vivo microchip that accesses the bloodstream via catheters and makes continuous, sensitive and specific detection feasible by fabricating the E-AB sensor (Fig. 3Ai) , along with the insertion of a continuous-flow diffusion filter (CDF) [49] . The filter prevents biofouling by excluding blood-borne interferents (e.g., albumin, immunoglobulin, and fibrinogen). The sensor achieved a LOD to doxorubicin (a chemotherapy drug) of 10 nM in buffer over a dynamic range of 0.01 to 10 mM. Within 45 s, the probe reached 90% saturation and then returned to within 10% of the baseline by 100 s. After intravenous injection of doxorubicin into anesthetised Sprague-Dawley rats, the sensor dosed increasing concentrations of doxorubicin (0 to 2 mg/m 2 ) over a period of 4.5 h (Fig. 3A iii). In a follow-up study, the microchip was integrated into a closed-loop system for precise control of drug concentrations in vivo [50, 51] . This was fabricated by equipping the sensor with a controller and an infusion pump. (Fig. 3B , upper side). Within 5-10 min, the system reached 95% of the concentration set point (Fig. 3B , dashed orange line) in live conscious rabbits, and this level could be maintained within 20% over an infusion period of approximately 2 h (Fig. 3B , bottom). The system automatically compensated for animal-to-animal PK variability, corrected for acute drug-drug interaction, and was easily adapted for rats with minimal modification. J o u r n a l P r e -p r o o f Wearable biosensors have been used for a long time for physical sensing and are attracting attention for continuous non-invasive capture of molecular data to retrieve more insightful physiological information from biofluids (e.g., sweat, tears, saliva, and interstitial fluid) [52, 53] . Human sweat is perhaps the most attractive carrier of biochemical biomarkers of potential diagnostic value [54] . Many research groups across the world are actively researching sweat biosensing [55] [56] [57] [58] . The recent advance by Gao et al. [58] put forward a wearable, flexible sensing platform for real-time capture of multiplexed sweat metabolites, electrolytes as well as skin temperature. The utility of sweat as a base medium for drug PK studies has been well proven in previous studies, making continuous detection of drug concentrations via wearable sweat sensors feasible [59, 60] . Real-time monitoring of drug levels via wearable sweat sensors was achieved in 2018 for the J o u r n a l P r e -p r o o f methylxanthine drug caffeine [61] . Caffeine has been adopted as the standard drug of choice for apnoea of prematurity [62, 63] . The sensor (Fig. 4A , left) employed a triple-electrode array patterned on a flexible polyethylene terephthalate substrate interfaced with a printed circuit board, while carbon nanotube (CNTs)/nafion films were adapted on the electrode surface to prevent biofouling and simultaneously improve sensitivity. Detected via differential pulse voltammetry, the sensor recorded real-time caffeine dynamics during exercise or iontophoresis, a sweat inducing technique ( Fig. 4A, right) . Through a sweatband worn around a healthy volunteer's wrist, confirmable caffeine physiological trends could be observed during exercise. This concept was very recently expanded to continuously collect levodopa in sweat to enable personalised management of Parkinson's disease [64] . This research applied gold dendritic nanostructures onto an evaporated Au/Cr conductive layer to increase the surface sensing area ( Interstitial fluid (ISF) is another class of biofluids that can be collected continuously and analysed via body-interfacing devices [65] . ISF-based sensors, such as the microneedle sensor, are garnering substantial interest because of their simple, rapid, continuous, minimally invasive sensing of chemical biomarkers of the body. Microneedle arrays only penetrate the stratum corneum layer of the skin and do not cause discomfort or draw blood as they do not reach the nerve endings and capillary blood vessels in the dermis [66] . Their application is primarily in diabetes management via continuous monitoring of glucose and transdermal drug delivery [67] [68] [69] . ISF-based sensors are rarely used in drug monitoring. However, the ISF microenvironment provides a compartment that is suitable for capturing the dynamics of therapeutic drugs as well as biomarkers. The feasibility of conducting TDM in ISF was confirmed by Kiang et al. with a comprehensive panel of 13 drugs, J o u r n a l P r e -p r o o f including antibiotics, immunosuppressant drugs, anticonvulsants, and chemotherapeutic drugs. This was determined using traditional techniques [70] . An early attempt to design a microneedle array prototype for drug monitoring was made in 2017, for theophylline, a methylxanthine drug used as a medicine for respiratory diseases [71] . The In the same year, an intradermal microneedle biosensor, highly promising as wearable, was developed for continuous tracking of penicillin (a β-lactam antibiotic) in vivo [73] . The microneedle arrays comprising four metallised sets of microneedles, three coated with gold and one with silver ( Fig. 4D, left) , with the gold WEs fabricated in five different layers [74] . Detection was facilitated by a pH-sensitive iridium oxide (IrOx) layer, which measured local changes in pH arising from β-lactam hydrolysis by β-lactamase, contained in an optimised enzyme hydrogel. The sensor had a LOD of 6.8 μM in 10 mM PBS, remained stable for 2 weeks at −20 , ℃ and withstood sterilisation (preventing potential infection in critically ill patients). During an approximately five-hour in vivo test, a healthy volunteer was asked to take five doses of penicillin (500 mg every 4−6 h), with the last dose taken just over 2 h into the study (indicated by dotted line in Fig. 4D , right). The three sensors (marked as red, green, and dark blue traces) responded similarly, with the potential of rising after the final dose, plateauing after an hour, and gradually reducing afterwards. Penicillin levels measured by the microneedle sensors were well tracked the levels were measured using both discrete blood and microdialysis sampling in vivo. The study still needs to establish the in vivo calibration curve, and thus, currently fails to quantify the magnitude of these changes. The performance of some typical in vitro and ex vivo sensors is summarised in Table 1 . In vivo sensors provide powerful tools for improving our understanding of inter-individual or intra-individual drug PK fluctuations through continuous physiologic monitoring, and could facilitate future advances in personalised therapy [75] . In vivo sensing can be effectively achieved via electrochemical measurement as electroactive contaminants are rare in vivo [76] . E-AB sensors perform well when challenged (in vitro and ex vivo) for hours in continuously flowing whole blood, making them a valuable anti-fouling single-step biosensor platform. Implantable sensors can measure one analyte continuously without the need for patient intervention, regardless of the patient's physiological state. The most popular clinical application for implantable sensors is glucose sensors for patients with diabetes [77] [78] [79] . In vivo continuous monitoring is informative but challenging to achieve. An in vivo sensor must have a robust design to perform reliably given the harsh environment, and should meet several key parameters. These parameters include reversibility (must be responsive within relevant time intervals), sensitivity (must be within an analyte's physiological range), selectivity (must specifically target the desired drug), and response time (must respond much faster than the analyte's metabolising rate). Regarding development of implantable sensors, biocompatibility, implantation, and removal are the additional key issues to consider. Biocompatibility determines the functional lifetime of a sensor, which partially depends on the shape and size of a sensor and the nanomaterials used. Implantation and removal are closely related to biocompatibility and also depend on whether the implanted device is intended to circulate in the blood or to be stationary at an anatomic site [80] . Advances in nanotechnology have contributed significantly to the miniaturisation and enhanced biocompatibility of sensors and driven the development of in vivo drug sensors [81, 82] . The next section illustrates recent advances in in vivo sensors for continuous study of drug PK in a live body, with special focus on how the microsystems overcome the hurdles to biocompatibility, stability, and calibration issues. E-AB sensors have recently been critical tools in the precise investigation of vivo drug metabolic and PK data in real time. In early 2017, the use of E-AB sensor for real-time, multi-hour detection of J o u r n a l P r e -p r o o f small-molecule drugs in awake bodies was achieved by Arroyo-Currás et al. [83] . The E-AB sensors employed a methylene blue modified freshly roughened gold electrode-bound aptamer as the sensing element to induce conformational change upon binding the analytes when interrogated via SWV (Fig. 5A, left) . Furthermore, the system employed a microporous polysulfone membrane to prevent fouling from blood cells, and a kinetic differential measurements approach to correct baseline drift. Emplaced in the external jugular vein of anesthetised rats (Fig. 5A, middle) , the E-AB sensor achieved a 3 s temporal resolution for real-time sensing of cancer chemotherapeutic doxorubicin. Interestingly, the in vivo sensors were able to collect precise drug (tobramycin) metabolic and PK data within the circulatory system in real-time in awake, ambulatory rats while they were feeding, drinking, and exploring the environment for up to 12 h upon single (Fig. 5A, right) and sequential injections. The upper part of Table 2 summarises the recent advances in E-AB sensors in vivo and the strategies adapted to address the key issues, such as increasing the active surface area, preventing signal gain fluctuations due to sensor-to-sensor fabrication variation, and preventing biofouling [83] [84] [85] [86] [87] . The significant advantages of E-AB sensors being an in vivo tool is that they allow precise identification of the inter and intra-animal PK variability over a multi-hour course that would otherwise be undetectable via conventional HPLC-MS methods. An in vivo study conducted on 12 individual rats revealed that there was a >50% animal-to-animal variance in the PK parameters of distribution, elimination, and maximum plasma concentration; and none of the parameters showed a correlation with body surface area [84] . These findings may explain why, in general, the current body-based approaches are inaccurate and failed to achieve effective drug efficacy. The advent of in vivo E-AB sensors empowered the development of in vivo feedback-controlled drug delivery systems [88] . The system (Fig. 5B, left) integrates selective E-AB sensors inserted into the right vein of anesthetised rats while an infusion line is inserted into the opposite vein, with a proportional-integral-derivative (PID) controller for computation of an appropriate dosing rate, and a syringe pump for delivery of the drug via intravenous infusion. Dosing is adjusted based on the difference between the drug concentration measured (Cp(t)) and a user-defined fixed or J o u r n a l P r e -p r o o f time-varying reference concentration (r(t)). By adjusting dosing every 7 s, the controller maintains precise tobramycin levels (±10%) over ~4 h even in the face of an ~3-fold fluctuation in the drug's elimination rate. This also enables predefined, near-identical PK profiles from animal to animal (Fig. 5B, right) . Interestingly, the system can accurately emulate the human drug exposure profiles in a rat model, which is achieved by generating a humanised rat profile using an average human PK profile, extracted from clinically-published PK data, to serve as a reference for guiding the infusion of tobramycin into a rat. This study opened up the possibility of investigating interspecies metabolic differences and evaluating the effects of human-mimicked PK profiles on human diseases being studied in animal models. High-precision feedback control of vancomycin concentration in vivo was also achieved very recently, with defined plasma vancomycin rapidly achieved (~30 min) and maintained at precise levels for over 5 h regardless of significant hour-to-hour changes in drug metabolism [89] . Evaluation of drug kinetics in organs is essential. The reason is that differential spatial and temporal drug distribution occurs through not only the human body but also through the cellular microenvironments of each organ following systemic administration [90] . Ogata et al. [91] developed a drug-sensing system supporting real-time monitoring of both drugs in in vivo and the respective organ functions over time. The microsystem comprises a conductive boron-doped diamond (BDD) with an ~40 μm tip diameter sensor for drug detection, a double-barrelled glass microcapillary glass microelectrode that monitored extra or intracellular electrical parameters resulting from ion-channel or ion-transporter activity (Fig. 5C, left) . In the live rat brain (Fig. 5C, middle) , the BDD microsensor accurately tracked the kinetics of bumetanide (a diuretic that can be ototoxic) over approximately 10 mins, with the local field potentials representing neuronal activity being monitored via the microelectrode in parallel (Fig. 5C, right) . Bumetanide concentrations within 0.6 and 5.7 μM could be sensitively detected. The system revealed a considerable difference between the local peak bumetanide concentrations in brains (measured via the BDD sensor) and systemic peak bumetanide plasma concentrations (measured via HPLC-MS/MS). The microsystem can equally be used to simultaneously monitor bumetanide concentrations in the J o u r n a l P r e -p r o o f guinea pig cochlea and its impact on hearing, with a 5 s time resolution, and similarly, to monitor the kinetics and actions of anti-epileptic lamotrigine and anticancer doxorubicin in organs. A significant advantage of this microsystem lies in its capability to track pharmacological and physiological responses that otherwise might remain undetected by conventional low-precision techniques. If used in earlier clinical trials for testing a drug candidate, the microsystem would facilitate the precise investigation of the maximal drug efficacy while trying to maintain minimal adverse events [92] . Increasing attention in healthcare is focused on multiplexing as disease occurrence and the therapeutic effects of drugs are often a result of an interplay between a variety of complex biological networks, including a large set of biological molecules [93] . Fully integrated biochip platforms are a promising tool for achieving multiplexing. Baj-Rossi et al. [94] developed a fully implantable biosensor array equipped for continuous monitoring of glucose and drug paracetamol (a pain reliever and fever reducer) in free moving animals. The one-centimetre square device (Fig. 5D, left) is comprised of three main components: a sensing platform containing four individual electrochemical sensors, three integrated circuits (the sensor's front-end circuit, a microcontroller, and the power/data manager), and a powering antenna [95] . Proper integration with the surrounding tissue was achieved by encapsulating the sensor within an external biocompatible packaging (Fig. 5D , middle). In vitro evaluation revealed a LOD of 34 ± 11 μM within 0-300 mΜ of paracetamol. Implantation of this device in the peritoneum of live mice, unfortunately, caused inflammation after 30 days due to a foreign body response, represented by relatively high levels of ATP and neutrophils, both serving as inflammatory mediators. In vivo evaluation was performed in the peritoneum of mice by injecting 400 mg/kg of paracetamol and the time/current profile obtained (Fig. 5D, right) showed that the signal rose after the injection and slowly reduced after around 30 min of measurements, with the trend roughly highlighted in the red dashed line. During the test, the mice could move freely without a wire tracker getting in the way, which caused noise. Because paracetamol was determined in the peritoneal fluid rather than in bloodstream, the research obtained only a nontypical PK profile at that time. Similarly, Hammoud et al. [96] designed an implantable biosensor platform prototype, attempting to achieve continuous monitoring of anti-epileptic drugs in real time by integrating: (i) the front-end circuit, hosting an inductive coil for absorbing energy from an external base station and communicating data to the base station; (ii) the power management block; and (iii) the read-out and control block; and (iv) the biosensor array. This implantable microsystem was intended for real-time monitoring of carbamazepine concentrations in vitro at the time, and its CDM capability remains to be proved. The performance of some typical in vivo sensors is summarised in Table 2 . J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f This study highlights the importance of continuous monitoring of therapeutic drugs in real time and reviews recent advances in biosensing technologies, from in vitro, ex vivo to in vivo, towards achieving this goal. Wearable sensors and in vivo sensors support direct, dynamic, and continuous biosensing of drug concentrations in vivo, and nanomaterial-based electrochemical biosensors are currently used only in an in vitro environment. In particular, wearable sensors evidently present a promising and exciting tool for drug detection as the entire process is executed automatically, continuously, and non-invasively or is at least minimally invasive. Previously, wearable sensors have also been used in point-of-care and in situ detection of suspected toxicity or drug abuse via sensing at the fingertips in a wearable glove [97] [98] [99] . In contrast, E-AB sensors are being proven as a universal approach by which an arbitrary molecular analyte can be monitored continuously. This capability is enabled by a high temporal resolution and independence of chemical reactivity towards the target. The seconds-resolved measurement frequency of E-AB sensors yields many hundreds of data points collected per PK profile, in contrast to the merely several time points PK produced via HPLC-MS/MS [84] and ELISAs. [102] . Another study on a multisensor-organs-on-chips platform demonstrate its capacity to constantly determine drug concentration and the drug's effect on human organs (e.g., liver, heart, or brain) along with a simultaneous evaluation of microenvironment parameters (pH, temperature) [103] . Nanoscale field-effect transistor-based biosensors are also promising because the primary challenge: Debye length limitations has been adequately addressed in several recent studies via the use of polymer J o u r n a l P r e -p r o o f polyethylene glycol [104] , or cross-linked polymer networked hydrogel [105] or aptamers [106] . The development of wearable and in vivo sensors to realise CDM is challenging. Three main issues should be taken into account when developing an in vivo sensing system: (i) quality (depending on the biocompatibility or inflammation due to the presence of the sensor inside the body, often a result of the sensor shape, size, and the nanomaterials used); (ii) calibration performance (including the specificity, sensitivity, and time resolution of the sensor); and (iii) stability of the sensor (depending on the fouling effects and the sufficiency of the supply power). In the preceding studies, devices were designed in small sizes, e.g., the <300 μm diameter electrodes in E-AB sensors and the one-centimetre square implantable chip. An external biocompatible integrating package guarantees proper integration of the sensor with its surrounding environment. Biofouling, the result of the accumulation of proteins, cells, or macromolecules on the sensors' surface through non-specific binding, was addressed using polysulfone membranes, a phosphatidylcholine modified monolayer, or miniaturised diffusion filters. These prevented blood cells from approaching the sensor surface while enabling rapid transport of target molecules. Strategies for reducing biofouling can be learned from an earlier review and two very recent studies [107] [108] [109] . The key issues and strategies for developing fully integrated biochips platform for advanced healthcare have been carefully discussed in an earlier study by Carrara et al. [110] , which covers nanomaterials for improving device sensitivity, selecting and immobilising bioreceptors, integration of bio and nanomaterials onto micro-arrays, electronics front-end, remote powering, device biocompatibility, and data security. CDM is promising for considerably improving therapeutic drug monitoring and reshaping our understanding of individual PK variation. It helps us understand how real drug concentrations change inside the body with maximum precision and to evaluate the potential effects of a given drug on the organs. Furthermore, when integrated with a feedback controller, it empowers us to adjust and maintain optimised drug dosing within its therapeutic window in response to minute-to-minute concentration changes in vivo. Given ongoing efforts at miniaturisation, in vivo sensors will evolve, to their full capacities, into implantable sensors in subsequent years. Together with wearable sensors, they will serve as critical tools for the continuous biosensing of drug concentrations in real time, with J o u r n a l P r e -p r o o f the final healthcare goal being to achieve remote, or even automated disease monitoring and management. As thus, we believe that CDM may become a future tool for achieving enhanced individualised therapy. However, wearable, implantable sensors and E-AB sensors are still in their proof-of-concept stages for application to drug determination. Effort is required to make the sensors more robust for use in complex biomatrices and further integrated for insertion into live bodies. Key parameters to improve the sensors' robustness include specificity, sensitivity, reproducibility, reusability, long-term stability against biofouling and biocompatibility. Furthermore, several key issues should be addressed to make the sensors more applicable and the idea of CDM as a future tool for individualised therapy more promising and feasible. The first issue is to enlarge the application of wearable and E-AB sensors into more drugs that have clearly shown their clinical needs of therapeutic drug monitoring to optimise dosing. This can be very beneficial to management of more types of diseases. Strategies may include the production of a variety of high-quality aptamers for use in E-AB sensors. The second related issue is clinical validity. The clinical validity of in vivo drug sensors has only recently been evaluated in animals. The next step is clinically validation on humans, during which one thing to consider is specie-to-specie metabolism variation towards a given drug. At the very later stage, extensive clinical trials are required if a drug sensor, being in vivo or wearable, is to enter the market. The successful entry of continuous glucose sensors into clinical practice is an excellent precedent for learning to transfer state-of-the-art CDM technologies. The last key issue is the vast amount of data captured during continuous drug sensing. This clearly requires attention to private data confidentiality, and big data processing and management. In recent years we have witnessed explosive developments in artificial intelligence (AI) and its applications in drug discovery and development. The significance of AI in making CDM a promising tool is twofold: (i) AI facilitates the analysis of the signals mass-produced during continuous operation at utmost speed while automatedly reducing background noise signals; (ii) AI is good at predicting and analysing complicated relationships, and thus, pharmaceutical scientists will be able to precisely mine the collected data to create accurate decision-making algorithms that can effectively guide clinically oriented investigations and deliver personalised therapy. The development of CDM technologies requires the combination of much multidisciplinary knowledge and expertise from areas such as the pharmaceutical sciences, electrical engineering, J o u r n a l P r e -p r o o f surface biochemistry, nanotechnology, medicine, and AI. With joint efforts, we believe that CDM will usher in an era of smart, automated, real-time, continuous management of the state of patients with a more precise personalised therapy. [ Precision medicine Therapeutic drug monitoring Best practice in therapeutic drug monitoring Review of the evidence to include TDM in the essential in vitro diagnostics list and prioritization of medicines to be monitored American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases Therapeutic drug monitoring for tomorrow Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry Therapeutic drug monitoring Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naïve Crohn's disease patients: the usefulness of rapid testing Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk Molecular immune pathogenesis and diagnosis of COVID-19 Recent advances and perspectives of nucleic acid detection for coronavirus Development and validation of a device for rapid monitoring of adalimumab in serum of patients with Crohn's disease Realizing the promise of personalized medicine Amperometric biosensors for clinical and therapeutic drug monitoring: a review Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring The future of drug trials is better data and continuous monitoring On-Site Therapeutic drug monitoring Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application An economic perspective on personalized medicine Detection methods and tools of administered J o u r n a l P r e -p r o o f anti-epileptic drugs -a review Electrochemical biosensors Biosensors market size, share & trends analysis report by application by technology by end use and segment forecasts Nanosensor technology applied to living plant systems Recent developments in nanosensors for imaging applications in biological systems In vivo biosensing: progress and perspectives Wearable multiplexed biosensor system toward continuous monitoring of metabolites Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module Optical and electrochemical sensors and biosensors for the detection of quinolones Electrochemical biosensors -sensor principles and architectures Bio/CMOS interfaces and co-design Electrochemical sensor and biosensor platforms based on advanced nanomaterials for biological and biomedical applications Continuous monitoring of naproxen by a cytochrome P450-based electrochemical sensor An IoT solution for online monitoring of anesthetics in human serum based on an integrated fluidic bioelectronic system Fabrication and optimization of fiber-based lithium sensor: a step toward wearable sensors for lithium drug monitoring in interstitial fluid In vitro selection of RNA molecules that bind specific ligands Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Preparation of electrode-immobilized, redox-modified oligonucleotides for electrochemical DNA and aptamer-based sensing Aptamers as therapeutics Aptamer-based biosensors and nanosensors for the detection of vascular endothelial growth factor (VEGF): a review Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic, electrochemical aptamer-based sensor Dual-reporter drift correction to enhance the performance of electrochemical aptamer-based sensors in whole blood Calibration-free electrochemical biosensors supporting accurate molecular measurements directly in undiluted whole blood Aptamer-based field-effect biosensor for tenofovir detection The memristive effect as a novelty in drug monitoring Real-time, aptamer-based tracking of circulating therapeutic agents in living animals Closed-loop control of circulating drug levels in live J o u r n a l P r e -p r o o f animals Drug delivery: Closed-loop dynamic dosing Wearable biosensors for healthcare monitoring Wearables in medicine Sweat: a sample with limited present applications and promising future in metabolomics Simultaneous monitoring of sweat and interstitial fluid using a single wearable biosensor platform Achievements and challenges for real-Time sensing of analytes in sweat within wearable platforms Wearable sensors for biochemical sweat analysis Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis Utility of noninvasive biomatrices in pharmacokinetic studies Noninvasive monitoring of plasma L-dopa concentrations using sweat samples in Parkinson's disease Methylxanthine drug monitoring with wearable sweat sensors Caffeine therapeutic drug monitoring is necessary and cost-effective Caffeine citrate: a review of its use in apnoea of prematurity Wearable sweat band for noninvasive levodopa monitoring Body-interfaced chemical sensors for noninvasive monitoring A practical guide to the development of microneedle systems -In clinical trials or on the market A graphene-based electrochemical device with thermo-responsive microneedles for diabetes monitoring and therapy Toward self-powered wearable adhesive skin patch with bendable microneedle array for transdermal drug delivery Microneedles for drug and vaccine delivery Therapeutic drug monitoring in interstitial fluid: a feasibility study using a comprehensive panel of drugs Rapid, low cost prototyping of transdermal devices for personal healthcare monitoring Wearable electrochemical microneedle sensor for continuous monitoring of levodopa: toward parkinson management Development of a minimally invasive microneedle-based sensor for continuous monitoring of β-lactam antibiotic concentrations in vivo a pilot study in humans of microneedle sensor arrays for continuous glucose monitoring Novel molecular and nanosensors for in vivo sensing Switch-based biosensors: a new approach towards real-time, in vivo molecular detection Biosensors for real-time in vivo measurements Emerging synergy between nanotechnology and implantable biosensors: a review Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: a post-market registry study Implantable nanosensors: toward continuous physiologic monitoring Biocompatible materials for continuous glucose monitoring devices A review on recent advancements in electrochemical biosensing using carbonaceous nanomaterials Real-time measurement of small molecules directly in awake, ambulatory animals Ultra-high-precision, in-vivo pharmacokinetic measurements highlight the need for and a route toward more highly personalized medicine High surface area electrodes generated via electrochemical roughening improve the signaling of electrochemical aptamer-based biosensors Subsecond-resolved molecular measurements in the living body using chronoamperometrically interrogated aptamer-based sensors A biomimetic phosphatidylcholine-terminated monolayer greatly improves the In vivo performance of electrochemical aptamer-based sensors High-precision control of plasma drug levels using feedback-controlled dosing Electrochemical aptamer-based sensors for improved therapeutic drug monitoring and high-precision, feedback-controlled drug delivery Pharmacokinetics in organs and the intact body: model validation and reduction A microsensing system for the in vivo real-time detection of local drug kinetics Real-time drug pharmacokinetics Evaluation of optical detection platforms for multiplexed detection of proteins and the need for point-of-care biosensors for clinical use In-vivo validation of fully implantable multi-panel devices for remote monitoring of metabolism Full fabrication and packaging of an implantable multi-panel device for monitoring of metabolites in small animals Towards an implantable bio-sensor platform for continuous real-time monitoring of anti-epileptic drugs Sensing at your fingertips: glove-based wearable chemical sensors Wearable electrochemical sensors for forensic and clinical applications Wearable electrochemical glove-based sensor for rapid and on-site detection of fentanyl Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations Advancements in SPR biosensing technology: an overview of recent trends in smart layers design, multiplexing concepts, continuous monitoring and in vivo sensing Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors Specific detection of biomolecules in physiological solutions using graphene transistor biosensors Hydrogel gate graphene field-effect transistors as multiplexed J o u r n a l P r e -p r o o f biosensors Aptamer-field-effect transistors overcome Debye length limitations for small-molecule sensing Methods for reducing biosensor membrane biofouling Impact of anti-biofouling surface coatings on the properties of nanomaterials and their biomedical applications An antifouling coating that enables affinity-based electrochemical biosensing in complex biological fluids Fully integrated biochip platforms for advanced healthcare The authors declare no conflict of interest related with this work.